New York State Teachers Retirement System Sells 3,636 Shares of DaVita Inc. (NYSE:DVA)

New York State Teachers Retirement System cut its position in DaVita Inc. (NYSE:DVA) by 5.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 65,221 shares of the company’s stock after selling 3,636 shares during the quarter. New York State Teachers Retirement System’s holdings in DaVita were worth $6,833,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. ABLE Financial Group LLC lifted its stake in shares of DaVita by 48.1% during the 4th quarter. ABLE Financial Group LLC now owns 7,244 shares of the company’s stock valued at $759,000 after buying an additional 2,353 shares in the last quarter. International Assets Investment Management LLC bought a new position in shares of DaVita in the fourth quarter worth $1,097,000. Arizona State Retirement System grew its position in shares of DaVita by 1.4% in the fourth quarter. Arizona State Retirement System now owns 15,056 shares of the company’s stock valued at $1,577,000 after purchasing an additional 210 shares in the last quarter. TIAA Trust National Association raised its stake in shares of DaVita by 29.7% during the 4th quarter. TIAA Trust National Association now owns 6,554 shares of the company’s stock valued at $687,000 after purchasing an additional 1,500 shares during the period. Finally, State of Michigan Retirement System lifted its holdings in DaVita by 0.6% during the 4th quarter. State of Michigan Retirement System now owns 15,939 shares of the company’s stock worth $1,670,000 after purchasing an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

DaVita stock opened at $130.42 on Friday. DaVita Inc. has a fifty-two week low of $71.51 and a fifty-two week high of $141.54. The firm’s fifty day moving average price is $128.95 and its 200-day moving average price is $107.88. The stock has a market cap of $11.44 billion, a P/E ratio of 17.62, a price-to-earnings-growth ratio of 1.17 and a beta of 1.04. The company has a debt-to-equity ratio of 6.65, a quick ratio of 1.13 and a current ratio of 1.19.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, February 13th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.53 by $0.34. The firm had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.01 billion. DaVita had a return on equity of 64.42% and a net margin of 5.70%. The company’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.11 earnings per share. On average, equities research analysts expect that DaVita Inc. will post 9.23 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other DaVita news, insider James O. Hearty sold 26,164 shares of DaVita stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the transaction, the insider now directly owns 20,264 shares of the company’s stock, valued at $2,424,384.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider James O. Hearty sold 26,164 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the transaction, the insider now directly owns 20,264 shares of the company’s stock, valued at $2,424,384.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kathleen Alyce Waters sold 11,285 shares of the business’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $120.73, for a total value of $1,362,438.05. Following the completion of the sale, the insider now directly owns 81,297 shares of the company’s stock, valued at approximately $9,814,986.81. The disclosure for this sale can be found here. Insiders sold a total of 134,540 shares of company stock valued at $16,551,071 over the last quarter. 1.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

DVA has been the subject of a number of recent analyst reports. UBS Group lifted their target price on DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a report on Wednesday, February 14th. Truist Financial increased their target price on shares of DaVita from $130.00 to $135.00 and gave the stock a “hold” rating in a research note on Tuesday, February 20th. Barclays started coverage on shares of DaVita in a research report on Wednesday, March 6th. They set an “equal weight” rating and a $133.00 price target for the company. StockNews.com raised DaVita from a “buy” rating to a “strong-buy” rating in a research note on Monday, April 8th. Finally, TheStreet upgraded DaVita from a “c+” rating to a “b-” rating in a research note on Wednesday, February 7th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DaVita has a consensus rating of “Moderate Buy” and a consensus price target of $118.50.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.